iQ-008 Accepted into NIH Preclinical Screening Platform for Pain (PSPP)

Updated: Nov 7, 2021


Delaware – May 2021, iQure Pharma Inc. (iQure), a company dedicated to the development of new pain management therapeutics, is proud to announce that its lead asset iQ-008, has been accepted into the prestigious NIH PSPP (part of the NIH HEAL InitiativeSM) program to identify and profile non-addictive therapeutics for pain.


iQ-008, a Triple Action Agent, is a promising therapeutic candidate being developed for the treatment of Neuropathic Pain. iQ-008 is a rationally designed multitargeting compound which in preclinical efficacy screening showed very promising profile in all in vivo pain models.


The Helping to End Addiction Long-term InitiativeSM, or NIH HEAL InitiativeSM, is an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. The PSPP is an efficient, rigorous, one-stop screening resource to accelerate discovery of effective, non-addictive, non-opioid pain therapies. The program consists of a fully NIH-funded, stepwise testing approach, including an assessment of in vitro binding studies and pharmacokinetic profiles, side effect profiles, abuse liability, and efficacy in models relevant to human pain conditions.


98 views

Recent Posts

See All